Table 1 Trial characteristics
Trial characteristic | Summary extraction: 2013–16, n (%) n = 69 | Detailed extraction: 2017–18, n (%) n = 91 | Total, n (%) n = 160 |
|---|---|---|---|
Purpose | |||
Screening | 6 (9%) | 10 (11%) | 16 (10%) |
Treatment | 51 (74%) | 65 (71%) | 116 (73%) |
Primary prevention | 12 (17%) | 16 (18%) | 28 (18%) |
Feasibility/Pilot trial | |||
Yes | 6 (9%) | 11 (12%) | 17 (11%) |
No | 63 (91%) | 80 (88%) | 143 (89%) |
Recruitment setting | |||
Primary care | 23 (33%) | 18 (20%) | 41 (26%) |
Secondary care | 46 (67%) | 73 (80%) | 119 (74%) |
Disease category | |||
Cancer | 17 (25%) | 30 (33%) | 47 (29%) |
Cardiovascular and stroke | 21 (30%) | 25 (27%) | 46 (29%) |
Pregnancy and childbirth | 4 (6%) | 5 (5%) | 9 (6%) |
Mental/neurological health | 6 (9%) | 6 (7%) | 12 (8%) |
Infection | 5 (7%) | 3 (3%) | 8 (5%) |
Endocrine and diabetes | 1 (1%) | 3 (3%) | 4 (3%) |
Inflammatory disorder | 2 (3%) | 3 (3%) | 5 (3%) |
Other | 13 (19%) | 16 (18%) | 29 (18%) |
Intervention | |||
Drug | 38 (55%) | 38 (42%) | 76 (48%) |
Surgical | 5 (7%) | 8 (9%) | 13 (8%) |
Other | 26 (38%) | 45 (49%) | 71 (44%) |
Primary outcome | |||
Survival related | 33 (48%) | 39 (43%) | 72 (45%) |
Other | 36 (52%) | 52 (57%) | 88 (55%) |
Randomisation | |||
Individual | 61 (88%) | 75 (82%) | 136 (85%) |
Cluster | 8 (12%) | 16 (18%) | 24 (15%) |
Trial size | |||
Median | 1103 | 2611 | 1590 |
Range | 41–170,432 | 53–6,000,000 | 41–6,000,000 |
1–500 | 21 (30%) | 20 (22%) | 41 (26%) |
500–5000 | 31 (45%) | 43 (47%) | 74 (46%) |
>5000 | 17 (25%) | 25 (27%) | 42 (26%) |
Unclear | 0 (0%) | 3 (3%) | 3 (2%) |
International accrual | |||
Yes | 13 (19%) | 19 (21%) | 32 (20%) |
No (UK only) | 56 (81%) | 69 (76%) | 125 (78%) |
Unclear | 0 (0%) | 3 (3%) | 3 (2%) |
Coordinated by registered clinical trials unit | |||
Yes | 40 (58%) | 63 (69%) | 103 (64%) |
No | 10 (14%) | 12 (13%) | 22 (14%) |
Unclear | 19 (28%) | 16 (18%) | 35 (22%) |
Highest profile journal (if primary report published) | |||
BMJ | NA | 2 (2%) | 2 (1%) |
JAMA | NA | 6 (7%) | 6 (4%) |
Lancet | NA | 16 (18%) | 16 (10%) |
Lancet-specialty | NA | 2 (2%) | 2 (1%) |
NEJM | NA | 3 (3%) | 3 (2%) |
Other | NA | 6 (7%) | 6 (4%) |
Not yet published | NA | 56 (62%) | 56 (35%) |
Not captured | 69 (100%) | NA | 69 (43%) |